Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
- Conditions
- Primary Open Angle GlaucomaIntraocular Pressure
- Registration Number
- NCT00864578
- Lead Sponsor
- Sooft Italia
- Brief Summary
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients. However, some patients cannot reach the target pressure despite a multitherapy with a combination of drugs, and are therefore addressed to surgical treatments. Forskolin is a natural compound that is a receptor-independent adenyl-cyclase activator, that increases intracellular cAMP. It has been shown to be able to decrease IOP after topical application, by a mechanism that is not used by the other drugs. Aim of the present study is to see whether a food supplement containing forskolin (KRONEK) has any effect on the IOP of POAG patients that cannot reach their target pressure, and are therefore on the waiting list for surgical intervention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Age: 30-70 Years
- Sex: both
- Pathology: POAG
- Characteristics: Target pressure not achieved with current treatments
- Concomitant ocular pathologies
- Previous ocular surgery
- Known hypersensitivity to any of the components in the KRONEK tablets
- Concomitant participation in other trials
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intraocular pressure Enrollment, 1, 2, 3, 4 weeks after initiation of treatment
- Secondary Outcome Measures
Name Time Method Intraocular pressure fluctuations during the day Enrollment, 1, 2, 3, 4 weeks after initiation of treatment
Trial Locations
- Locations (1)
Ophthalmology Department of the University Clinic
🇮🇹Bari, Italy